HIGHLIGHTS
SUMMARY
Cardiovascular disease is an inflammatory disorder that may benefit from appropriate modulation of inflammation. Systemic treatments lower cardiac events but have serious adverse effects. Localized modulation of inflammation in current standard treatments such as bypass grafting may more effectively treat CAD. The present study investigated a bioactive vascular graft coated with the macrophage polarizing cytokine interleukin-4. These grafts repolarize macrophages to anti-inflammatory phenotypes, leading to modulation of the pro-inflammatory microenvironment and ultimately to a reduction of foreign body encapsulation and inhibition of neointimal hyperplasia development. These resulting functional improvements have significant implications for the next generation of synthetic vascular grafts. 
METHODS
PIII SURFACE TREATMENT. Surface modification of electrospun polycaprolactone (PCL) scaffolds was conducted by using PIII as previously described (8) .
Briefly, nitrogen was admitted into a custom-built vacuum chamber to a working pressure of 2 Â 10 
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Immunomodulatory Vascular Grafts Tan et al. Tan et al. (bottom row) macrophages. CD68 stained in green, CD206 stained in orange, and MHC Class II stained in purple. Dotted lines represent the interface between tissue (above) and implant (below). Scale bar represents 60mm; n ¼ 5 per group. IHC ¼ immunohistochemical; other abbreviations as in Figure 1 . group. Abbreviations as in Figure 1 .
Tan et al. Figures 7A and 7B ). In addition, Tan et al.
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Immunomodulatory Vascular Grafts In a vascular graft context, inflammatory processes drive both fibrous encapsulation and neointimal Tan et al.
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Immunomodulatory Vascular Grafts hyperplasia leading to graft failure. Adventitial capsule thickness on bioactive IL-4 grafts was 50 AE 1% less than control ( Figure 8A ). In addition, neointimal hyperplasia in bioactive IL-4 grafts was significantly less throughout the length of the graft ( Figure 8B ). The greatest decreases were observed at the proximal and distal anastomoses, with a reduction of 69 AE 6.7% and 61 AE 6.1%, respectively, relative to control. The midsection of the graft also saw significantly less hyperplasia (51 AE 9.6%) compared with control ( Figure 8C ).
No significant changes to re-endothelialization were observed between the grafts (Supplemental Tan et al.
